Anika Therapeut: (NASD: ANIK)

$14.40

0.25 (1.77%)

Volume 64,714

May 17 04:00 PM ET

Zacks Rank: 1-Strong Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		14.07 - 14.46
	
		52wk Low - High
		9.13 - 16.29
	
		Previous Close
		14.15
	
		Avg. Volume
		68,090
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		200.43 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.47
	
		PE (Forward)
		13.85
	
		Current Year Est.
		1.04
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		1
Strong Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 03/27/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            13.85
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            1.04
                        
                            Current Quarter Estimate
                            0.29
                        
                            Most Accurate Estimate
                            0.29
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            1.00
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissue.  These products are based on hyaluronic acid, a naturally-occurring, biocompatible polymer found in the body. Due to its unique properties, hyaluronic acid plays an important role in numerous physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues and the transport of molecules to and within cells.   
Full ANIK Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ANIK Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.29	0.20	1.04	1.30
Number of Estimates	1	1	1	1
Low Estimate	0.29	0.20	1.04	1.30
High Estimate	0.29	0.20	1.04	NA
Year Ago EPS	0.26	0.11	0.93	1.04
EPS Growth	11.54%	81.82%	11.83%	25.00%

More ANIK Estimates

Average Earnings Estimates for ANIK

EPS Growth for ANIK

Industry Analysis

Name	Symbol	Previous Close
ANIKA THERAPEUT	ANIK	14.40
AETERNA ZENTARS	AEZS	2.10
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALEXION PHARMA	ALXN	102.90
ALKERMES INC	ALKS	31.69
ALNYLAM PHARMA	ALNY	27.44

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

SGEN's Adcetris under FDA Review

May 16, 2013

Pediatric Approval for MDCO/BMY's Recothrom

May 15, 2013

Amgen to Set Up JV in China

May 14, 2013

Disappointing 1Q Earnings for IART

May 10, 2013

Wider-than-Expected Loss at Dynavax

May 07, 2013

Zacks #1 Rank Additions for Thursday

May 02, 2013

Zacks #5 Rank Additions for Monday

Jun 04, 2012

Zacks #5 Rank Additions for Wednesday

May 30, 2012

More ANIK Zacks Commentary

Financials

EPS TTM	1.00
Sales	71
Net Income	13
Price/Earnings	14.40
Price/Book	1.78
Price/Cash Flow	11.17
Price/Sales	2.77

More ANIK Financials

News

Anika Therapeutics Q1 net income up - Datamonitor

May 13, 2013

Buyers Accumulate Shares of Anika Therapeutics, Up 2.6% - Financial News Network Online - Market Movers

May 6, 2013

Anika Therapeutics IncCorporate Event Announcement Notice - Wall Street Horizon

May 2, 2013

Anika Therapeutics IncCorporate Event Announcement Notice - Wall Street Horizon

May 1, 2013

Anika Therapeutics Reports First-Quarter 2013 Financial Results - Businesswire

May 1, 2013

Anika Therapeutics Makes a Move: Up 2.2% - Financial News Network Online - Market Movers

Apr 29, 2013

Anika Therapeutics Makes a Move: Down 2.6% - Financial News Network Online - Market Movers

Apr 22, 2013

Buyers Accumulate Shares of Anika Therapeutics, Up 1.5% - Financial News Network Online - Market Movers

Apr 19, 2013

See All News Stories on ANIK

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	2
Average Target Price	19.00
Industry Rank by ABR	91 out of 265
Rank in Industry	1 out of 155

More ANIK Broker Recommendations

Day Low - High	14.07 - 14.46
52wk Low - High	9.13 - 16.29
Previous Close	14.15
Avg. Volume	68,090
Industry	MED-BIOMED/GENE
Market Cap	200.43 M
Div - Yield	0.00 - 0.00
Beta	1.47
PE (Forward)	13.85
Current Year Est.	1.04
Quarterly Earnings ESP	0.00%

PE (Forward)	13.85
PEG Ratio	NA
Current Year Est.	1.04
Current Quarter Estimate	0.29
Most Accurate Estimate	0.29
Earnings ESP	0.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	1.00
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Anika Therapeut: (NASD: ANIK)

$14.40

0.25 (1.77%)

Volume 64,714

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description